Compulsory Vaccination Against Terrorist Attack Is Unjustified, Author Says

Article

The compulsory use of vaccines to prevent the effects of a bioterrorist attack seems to be based on an unproved threat, according to an editorial in this week's British Medical Journal.

 

In 1997 the United States began a compulsory anthrax vaccination program for military personnel. In 2002, a similar program also involving civilians, was started against smallpox. Yet these programs rely on old vaccines for which relatively few data exist, writes Tom Jefferson.

 

For instance, no large scale trial of the US anthrax vaccine (AVA) has ever been conducted, and trials of the current smallpox vaccine have recently been halted because of safety concerns. Despite this, the website of the United States anthrax vaccine immunization program claims proved protection against inhalation anthrax, says the author. Newer vaccines are currently being developed but are a long way from field testing.

 

"Although field trials are expensive and complex, investment in evaluation and in better and safer vaccines surely must be a requisite to have credible compulsory immunization programs involving huge numbers of adults of reproductive age," adds the author. "Until such time, the choice of whether to be vaccinated or not should be left to the individual."

 

To view the full editorial, go to:

http://press.psprings.co.uk/bmj/september/edit524.pdf

 

Reference: BMJ 4 September 2004 edition. Editorial: Bioterrorism and compulsory vaccination BMJ Volume 329, pp 524-5.

 

Source: British Medical Journal

 

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content